Malignant Pleural Mesothelioma: Socioeconomic and Clinical Aspects

被引:0
|
作者
Pandey, Swaroop Kumar [1 ]
Yadav, Neha [2 ]
Mishra, Anuja [1 ]
Sohal, Jagdip Singh [3 ]
Thakur, Komal [3 ]
Dwivedi-Agnihotri, Hemlata [2 ]
机构
[1] GLA Univ, Inst Appl Sci & Humanities, Dept Biotechnol, Mathura 281406, India
[2] Univ Delhi, Dept Biophys, South Campus, New Delhi 110021, India
[3] GLA Univ, Ctr Vaccine & Diagnost Res, Mathura, India
关键词
Pleura; mesothelioma; socioeconomic burden; asbestos; carbon nanotubes; INTENSITY-MODULATED RADIOTHERAPY; PHASE-II TRIAL; EXTRAPLEURAL PNEUMONECTOMY; MULTIMODALITY THERAPY; INTERVENTION SITES; ASBESTOS BAN; OPEN-LABEL; MULTICENTER; RADIATION; IMMUNOTHERAPY;
D O I
10.2174/0115733947315242240718074626
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pleural malignancy is an aggressive malignancy of the pleural surface and is primarily associated with asbestos exposure. Malignant pleural mesothelioma (MPM) is an invasive form of mesothelioma and resistant to conventional therapy. Recently, it has also been reported that carbon nanotube (CNTs) exposure can induce inflammation and fibrosis of the pleura and induce tumor development pre-clinical model. Although several strategies like immunotherapy (Dendritic cells, immune checkpoint inhibitors, CAR-T cell therapy), and viral therapy are being employed for the management of MPM. However, poor prognosis and limited treatment options make the problem worse. Apart from clinical challenges, industrial and socioeconomic challenges are key factors for the patients as they are mainly industry workers or their associates. This article is focused on industrial, clinical and socioeconomic challenges associated with malignant pleural mesothelioma (MPM) patients and available opportunities.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Standards, Options and Recommendations (SOR) for clinical care of malignant pleural mesothelioma
    Ruffie, P
    Lehmann, M
    Galateau-Salle, F
    Lagrange, JL
    Pairon, JC
    BULLETIN DU CANCER, 1998, 85 (06) : 545 - 561
  • [22] Radiation Therapy for Malignant Pleural Mesothelioma
    Rosenzweig, Kenneth E.
    THORACIC SURGERY CLINICS, 2020, 30 (04) : 473 - +
  • [23] Surgical Management of Malignant Pleural Mesothelioma
    Yanagawa, Jane
    Rusch, Valerie
    THORACIC SURGERY CLINICS, 2013, 23 (01) : 73 - +
  • [24] Advances in the treatment of malignant pleural mesothelioma
    Sterman, DH
    Kaiser, LR
    Albelda, SM
    CHEST, 1999, 116 (02) : 504 - 520
  • [25] Emerging therapies in malignant pleural mesothelioma
    Cinausero, Marika
    Rihawi, Karim
    Cortiula, Francesco
    Follador, Alessandro
    Fasola, Gianpiero
    Ardizzoni, Andrea
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2019, 144
  • [26] Advances in Immunotherapy of Malignant Pleural Mesothelioma
    Liao, Dongying
    Yu, Yongchao
    Mei, Qingyun
    Wang, Ziwei
    Li, Xiaojiang
    Jia, Yingjie
    Kong, Fanming
    ONCOTARGETS AND THERAPY, 2021, 14 : 4477 - 4484
  • [27] Immunotherapy in Malignant Pleural Mesothelioma
    de Gooijer, Cornedine J.
    Borm, Frank J.
    Scherpereel, Arnaud
    Baas, Paul
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [28] Update on Malignant Pleural Mesothelioma
    Campbell, Nicholas Paul
    Kindler, Hedy Lee
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 32 (01) : 102 - 110
  • [29] Chemotherapy of malignant pleural mesothelioma
    Bertino, Pietro
    Carbone, Michele
    Pass, Harvey
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (01) : 99 - 107
  • [30] Management of malignant pleural mesothelioma
    Nowak, Anna K.
    Bydder, Sean
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2007, 3 (04) : 177 - 186